US EditionPublished • loading... • Updated
Texas, Florida Sue FDA over Abortion Pill Approval
Texas and Florida argue the FDA failed to properly evaluate mifepristone safety and claim the Comstock Act prohibits mailing abortion drugs, seeking to restrict nationwide access.
- On Dec. 9, Texas Attorney General Ken Paxton filed a federal complaint in Wichita Falls, arguing the FDA did not properly evaluate mifepristone's safety and effectiveness.
- Targeting recent FDA policy shifts, the complaint challenges mail dispensing of abortion drugs, filed days after Texas House Bill 7 took effect.
- Medical evidence shows mifepristone with misoprostol is the most common abortion method in the U.S., and the FDA told The New York Times generics must be approved if identical.
- A federal ruling could devastate abortion access nationwide by restricting mifepristone, including in states where abortion remains legal, and undermine blue states' abortion shield laws, Shellie Hayes-McMahon warned.
- In recent years, legal challenges have targeted mifepristone as the new frontier after Roe's fall, with the U.S. Supreme Court rejecting the Amarillo case last year for lack of standing, and Mary Ziegler said the anti-abortion movement now relies on courts as litigation seems more promising.
Insights by Ground AI
11 Articles
11 Articles
Texas and Florida Sue FDA in New Bid to Block Abortion Pill Access
Texas launched a lawsuit against the U.S. Food and Drug Administration last week over the agency’s approval of mifepristone, marking the state’s latest effort to crack down on access to abortion pills. Joined by Florida, Texas Attorney General Ken Paxton filed the case on Dec. 9 in federal court in Wichita Falls. The two states argued in a 120-page complaint that the FDA did not properly evaluate mifepristone’s safety and effectiveness when appr…
Coverage Details
Total News Sources11
Leaning Left3Leaning Right1Center7Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 27%
C 64%
Factuality
To view factuality data please Upgrade to Premium
